These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 29962813)

  • 41. Direct-acting agents for hepatitis C virus before and after liver transplantation.
    Sugawara Y; Hibi T
    Biosci Trends; 2018 Jan; 11(6):606-611. PubMed ID: 29238003
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis.
    Vukotic R; Conti F; Fagiuoli S; Morelli MC; Pasulo L; Colpani M; Foschi FG; Berardi S; Pianta P; Mangano M; Donato MF; Malinverno F; Monico S; Tamè M; Mazzella G; Belli LS; Viganò R; Carrai P; Burra P; Russo FP; Lenci I; Toniutto P; Merli M; Loiacono L; Iemmolo R; Degli Antoni AM; Romano A; Picciotto A; Rendina M; Andreone P;
    J Viral Hepat; 2017 Oct; 24(10):858-864. PubMed ID: 28370880
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs.
    Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Dhersin JS; Yazdanpanah Y
    Hepatology; 2016 Apr; 63(4):1090-101. PubMed ID: 26390137
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Shear-wave elastography for the assessment of liver fibrosis in liver transplant recipients treated for hepatitis C virus recurrence.
    Korda D; Lenard ZM; Gerlei Z; Jakab Z; Haboub-Sandil A; Wagner L; Varga M; Cseprekal O; Marton A; Horvathy D; Takacs S; Doros A; Mathe Z
    Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):27-32. PubMed ID: 29049126
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
    Wasitthankasem R; Vichaiwattana P; Siripon N; Posuwan N; Auphimai C; Klinfueng S; Thanetkongtong N; Vuthitanachot V; Saiyatha S; Thongmai C; Sochoo S; Pongsuwan N; Poovorawan K; Tangkijvanich P; Poovorawan Y
    PLoS One; 2018; 13(4):e0196301. PubMed ID: 29689073
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatitis C Virus in Children: Deferring Treatment in Expectation of Direct-Acting Antiviral Agents.
    Granot E; Sokal EM
    Isr Med Assoc J; 2015 Nov; 17(11):707-11. PubMed ID: 26757569
    [TBL] [Abstract][Full Text] [Related]  

  • 47. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
    Sogni P; Gilbert C; Lacombe K; Piroth L; Rosenthal E; Miailhes P; Gervais A; Esterle L; Chas J; Poizot-Martin I; Dominguez S; Simon A; Morlat P; Neau D; Zucman D; Bouchaud O; Lascoux-Combe C; Bani-Sadr F; Alric L; Goujard C; Vittecoq D; Billaud E; Aumaître H; Boué F; Valantin MA; Dabis F; Salmon D; Wittkop L
    Clin Infect Dis; 2016 Sep; 63(6):763-770. PubMed ID: 27317796
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"?
    Pradat P; Pugliese P; Poizot-Martin I; Valantin MA; Cuzin L; Reynes J; Billaud E; Huleux T; Bani-Sadr F; Rey D; Frésard A; Jacomet C; Duvivier C; Cheret A; Hustache-Mathieu L; Hoen B; Cabié A; Cotte L;
    J Infect; 2017 Sep; 75(3):234-241. PubMed ID: 28579302
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [ANRS-fibrovic and homavic: role of non invasive markers of liver fibrosis and insulin resistance during antiviral treatment in HIV-HCV co-infected patients from ANRS HC 02 RIVABIC trial].
    Halfon P; Pénaranda G; Cacoub P
    Gastroenterol Clin Biol; 2009 Mar; 33 Suppl 2():S113-7. PubMed ID: 19375039
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.
    El-Sherif O; Jiang ZG; Tapper EB; Huang KC; Zhong A; Osinusi A; Charlton M; Manns M; Afdhal NH; Mukamal K; McHutchison J; Brainard DM; Terrault N; Curry MP
    Gastroenterology; 2018 Jun; 154(8):2111-2121.e8. PubMed ID: 29535028
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
    Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
    Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatitis C: epidemiology, diagnosis, natural history and therapy.
    Pol S; Vallet-Pichard A; Corouge M; Mallet VO
    Contrib Nephrol; 2012; 176():1-9. PubMed ID: 22310776
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Changes of non-invasive markers and FibroScan values during HCV treatment.
    Vergniol J; Foucher J; Castéra L; Bernard PH; Tournan R; Terrebonne E; Chanteloup E; Merrouche W; Couzigou P; de Lédinghen V
    J Viral Hepat; 2009 Feb; 16(2):132-40. PubMed ID: 19175875
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chronic hepatitis C and liver fibrosis.
    Sebastiani G; Gkouvatsos K; Pantopoulos K
    World J Gastroenterol; 2014 Aug; 20(32):11033-53. PubMed ID: 25170193
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
    Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
    Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
    [TBL] [Abstract][Full Text] [Related]  

  • 56. EASL recommendations on treatment of hepatitis C: Final update of the series
    ; ; ;
    J Hepatol; 2020 Nov; 73(5):1170-1218. PubMed ID: 32956768
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
    Curry MP; Forns X; Chung RT; Terrault NA; Brown R; Fenkel JM; Gordon F; O'Leary J; Kuo A; Schiano T; Everson G; Schiff E; Befeler A; Gane E; Saab S; McHutchison JG; Subramanian GM; Symonds WT; Denning J; McNair L; Arterburn S; Svarovskaia E; Moonka D; Afdhal N
    Gastroenterology; 2015 Jan; 148(1):100-107.e1. PubMed ID: 25261839
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Role of Liver Segment-to-Spleen Volume Ratio in the Staging of Hepatic Fibrosis in Patients with Hepatitis C Virus Infection.
    Lotan E; Raskin SP; Amitai MM; Kleinbaum Y; Veitsman E; Weiss P; Cohen-Ezra O; Berdichevski T; Ben-Ari Z
    Isr Med Assoc J; 2017 Apr; 19(4):251-256. PubMed ID: 28480681
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New approaches in the treatment of hepatitis C.
    González-Grande R; Jiménez-Pérez M; González Arjona C; Mostazo Torres J
    World J Gastroenterol; 2016 Jan; 22(4):1421-32. PubMed ID: 26819511
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study.
    Ippolito AM; Milella M; Messina V; Conti F; Cozzolongo R; Morisco F; Brancaccio G; Barone M; Santantonio T; Masetti C; Tundo P; Smedile A; Carretta V; Gatti P; Termite AP; Valvano MR; Bruno G; Fabrizio C; Andreone P; Zappimbulso M; Gaeta GB; Napoli N; Fontanella L; Lauletta G; Cuccorese G; Metrangolo A; Francavilla R; Ciracì E; Rizzo S; Andriulli A
    Dig Liver Dis; 2017 Sep; 49(9):1022-1028. PubMed ID: 28487083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.